Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bilastine + dextromethorphan + phenylephrine
- Development stage
- Unknown
- Lead developer
- Fawn
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Obalix Plus is an oral combination syrup marketed by Fawn Incor for the symptomatic relief of cough, common cold, allergic rhinitis, and nasal congestion. It contains three active ingredients: bilastine, a second-generation selective histamine H1 receptor antagonist that alleviates allergy symptoms such as sneezing and runny nose; dextromethorphan, a centrally acting cough suppressant that acts as a sigma-1 receptor agonist and NMDA receptor antagonist to reduce the cough reflex; and phenylephrine, a selective alpha-1 adrenergic receptor agonist that acts as a decongestant by constricting blood vessels in the nasal passages to relieve congestion.
- Brand names
- Obalix Plus
- Other names
- OBALIX PLUS Syrup
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)SIGMAR1 (Sigma non-opioid intracellular receptor 1)ADRA1A (α1A)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on bilastine + dextromethorphan + phenylephrine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bilastine + dextromethorphan + phenylephrine.